United States RE38551: Scope, Claims, and Patent Landscape
What is US RE38551 and what does it claim?
US RE38551 is a reissue patent with a claims set directed to a specific class of stereochemically defined amide compounds, limited aromatic substitution patterns, and downstream use claims for anticonvulsant therapy in CNS disorders. The claim language you provided defines (i) compound scope by a core scaffold and substitution variables, (ii) stereochemical scope restricted to the R configuration and further constrained to “substantially enantiopure” / minimum R-enantiomer content, and (iii) method and composition scope for CNS disorder treatment.
Claim-by-claim scope (as provided)
| Claim |
Claim type |
Scope-defining limitations (verbatim meaning) |
| 1 |
Compound |
R configuration; formula with variable aromatic group Ar (phenyl unsubstituted or substituted by at least one halo); Q is lower alkoxy; Q1 is methyl |
| 2 |
Compound |
“Substantially enantiopure” (imposes stereochemical purity on Claim 1 compounds) |
| 3 |
Compound |
Q is lower alkoxy containing 1-3 carbons |
| 4 |
Compound |
Q is methoxy (special case of Claim 3) |
| 5 |
Compound |
Ar is unsubstituted phenyl |
| 6 |
Compound |
halo is fluoro (special case of “at least one halo group”) |
| 7 |
Compound |
Q is alkoxy containing 1-3 carbons AND Ar is unsubstituted phenyl |
| 8 |
Compound (example/narrow species) |
Explicit identity: (R)-N-Benzyl 2-Acetamido-3-methoxypropionamide |
| 9 |
Compound |
At least 90% (w/w) R stereoisomer (purity threshold tied to Claim 8 or the species as drafted) |
| 10 |
Composition |
Therapeutic composition with anticonvulsant effective amount of a compound per Claims 1-9 plus pharmaceutical carrier |
| 11 |
Method |
Treat CNS disorders in an animal via administration of an anticonvulsant effective amount of a compound per Claims 1-9 |
| 12 |
Method |
Animal is a mammal |
| 13 |
Method |
Mammal is a human |
How does the reissue claims set narrow the chemistry?
The claims impose three orthogonal narrowing axes:
1) Absolute stereochemistry
- Claim 1 limits to “compound in the R configuration.”
- Claim 2 adds “substantially enantiopure,” which excludes racemic or non-enantiopure material even if the R configuration is present.
- Claim 9 adds a quantitative purity floor: ≥90% (w/w) R stereoisomer.
Practical infringement leverage: even if a competitor makes the same scaffold in mixed or enriched but below 90% R, the claims as written can fall outside Claim 9 (and potentially outside Claim 2 depending on how “substantially enantiopure” is construed).
2) Substitution constraints on Ar and halo
- Claim 1 allows Ar = phenyl that is unsubstituted or substituted with at least one halo.
- Claim 6 narrows halo to fluoro.
- Claim 5 narrows Ar to unsubstituted phenyl.
- Claim 7 combines Ar unsubstituted phenyl with the Q carbon-number band.
Practical infringement leverage: freedom to substitute other halogens (chloro/bromo/iodo) is explicitly permitted by Claim 1 (because it requires “at least one halo group” without restricting identity). However, if a competitor uses a fluorinated pattern, Claim 6 is directly in play.
3) Q alkoxy identity and carbon count
- Claim 1: Q is lower alkoxy.
- Claim 3: Q is lower alkoxy with 1-3 carbons.
- Claim 4: Q is methoxy (1-carbon alkoxy).
- Claim 8: fixes Q implicitly at methoxy by specifying the compound: (R)-N-Benzyl 2-Acetamido-3-methoxypropionamide.
Practical infringement leverage: the claim set is not only species-specific (Claim 8) but also includes broader genus coverage through Q being lower alkoxy (1-3 carbons) and halo/Ar possibilities.
Where is the claim “center of gravity”?
The “center of gravity” is the specific R-enantiomer of N-benzyl 2-acetamido-3-methoxypropionamide, because it is called out explicitly (Claim 8) and has an additional quantitative restriction (Claim 9). This is the most commercially legible target for competitors and generic entrants who may attempt to launch stereochemically enriched versions.
Key species anchors
- Claim 8: (R)-N-Benzyl 2-Acetamido-3-methoxypropionamide
- Claim 9: same species (as drafted) with ≥90% (w/w) R stereoisomer
Genus coverage anchors
- Claims 1-7 cover a broader set of related R-configured compounds:
- scaffold with Ar as phenyl with optionally halo substitution
- Q as lower alkoxy (and further narrowed to 1-3 carbons)
- Q1 = methyl
- special cases: methoxy (Claim 4), unsubstituted phenyl (Claim 5/7), and fluoro halo (Claim 6)
How do the therapy claims expand reach beyond chemistry?
The downstream claims expand from compounds into enforceable commercial territories in two steps.
Composition claim (Claim 10)
- A “therapeutic composition” with:
- anticonvulsant effective amount
- pharmaceutical carrier
- of compounds according to Claims 1-9
This captures dosage-form marketing and “finished product” supply, assuming the product’s active is within the compound scope.
Method of treatment claims (Claims 11-13)
- Claim 11: treat central nervous system disorders in an animal by administering an anticonvulsant effective amount of the claimed compound
- Claim 12: animal is a mammal
- Claim 13: mammal is human
Practical infringement leverage: method claims can cover clinical use and label-driven administration. They are often asserted in parallel with composition claims if the product is within the active scope.
What is the enforceable patent “shape” for R-enantiomer products?
This reissue set is structured so that a competitor must clear multiple hurdles simultaneously:
- R configuration (not S or racemate)
- enantiopurity (substantially enantiopure; plus an explicit ≥90% threshold if Claim 9 is used)
- substitution match (Ar and Q definitions)
- use match (anticonvulsant effective treatment of CNS disorders, with animal/mammal/human scope)
That combination narrows the potential design space for “around” strategies: changing absolute stereochemistry (switching to S) is the most direct route, but it likely changes pharmacology and may be commercially unacceptable. Adjusting Q from methoxy to non-methoxy lower alkoxy (still 1-3 carbons) could avoid Claim 8 and potentially Claim 4 while still falling under Claims 1-3. Adjusting Ar substitution may avoid certain dependent claims but remains within Claim 1 if halo substitution remains.
What does the claim set imply for design-around strategies?
Based on the dependent claim structure, the following boundaries are embedded in the claims as provided:
- To avoid Claim 4 (methoxy): use an alkoxy Q that is lower alkoxy with 1-3 carbons but not methoxy (for example, ethoxy or propoxy would still satisfy Claim 3 if it keeps carbon count 1-3). That may avoid Claim 4 and Claim 8/9 only if the active is no longer the explicit methoxy species.
- To avoid Claim 5/7 (unsubstituted phenyl): introduce halo substitution on phenyl to step outside those dependents while still satisfying Claim 1.
- To avoid Claim 6 (fluoro): use non-fluoro halo substitution (chloros, bromos, etc.). Still within Claim 1 if “at least one halo group” remains.
- To avoid Claim 2/9 (enantiopurity constraints): formulate racemate or R content below the stated threshold. However, that could be interpreted as outside Claim 2 depending on how “substantially enantiopure” is evaluated.
- To avoid method/composition claims: even if chemistry is partially outside scope, the product must also avoid being administered/marketed as an anticonvulsant effective treatment for CNS disorders in humans, which is typically label and physician-driven.
What is the patent landscape around US RE38551?
A complete US landscape requires the reissue patent’s bibliographic data, priority/application family, claim numbering at reissue, and the prosecution history; it also requires mapping to related patents in the same family and to other third-party patents covering stereoisomeric anticonvulsant compounds and CNS indication uses. None of that bibliographic and family context is included in the prompt. Without it, a reliable landscape cannot be produced.
Given only the claim text you supplied, the only defensible “landscape” characterization is the internal one: US RE38551 positions itself as a stereochemically constrained anticonvulsant IP shield spanning both active ingredient and downstream dosage/use claims. The enforceable surface is therefore directed at:
- R-configured, lower-alkoxy, methyl-Q1 scaffold analogs with phenyl/halo aromatic substitution (compound claims)
- and at anticonvulsant CNS use in mammals and humans (composition and method claims).
Where are the highest litigation leverage points in this claim set?
Litigation leverage typically tracks the narrowest, most specific and commercially salient claims.
- Claim 8 + Claim 9: the explicit compound (R)-N-Benzyl 2-Acetamido-3-methoxypropionamide and ≥90% (w/w) R.
- Claim 1: genus coverage of all R-configured analogs fitting the Ar/Q/Q1 definitions.
- Claims 10-13: downstream ability to assert against both product and prescribing/administered therapy.
For enforcement planning, these points indicate where claim construction disputes on stereochemical purity, Ar substitution, and alkoxy identity would matter most.
Key Takeaways
- US RE38551 claims a stereochemically constrained R-configured compound class with Ar = phenyl (unsubstituted or halo-substituted), Q = lower alkoxy (specifically 1-3 carbons, including methoxy), and Q1 = methyl.
- The set contains both genus coverage (Claims 1-7) and species focus (Claim 8) with a quantitative stereochemical requirement (≥90% R, Claim 9).
- Enforcement reach extends into dosage forms (Claim 10) and therapeutic method for CNS disorders across animal, mammal, and human (Claims 11-13).
- The most litigation-relevant anchors are Claim 8/9 and the R-enantiopurity constraints.
FAQs
-
Does US RE38551 cover racemic mixtures?
The claims require R configuration (Claim 1) and further require “substantially enantiopure” (Claim 2), with a separate quantitative R threshold of ≥90% (Claim 9).
-
Is methoxy (Q = OCH3) explicitly claimed?
Yes. Q = methoxy is a dependent claim (Claim 4), and the specific methoxy compound is expressly named in Claim 8.
-
Can Ar be halogen-substituted phenyl?
Yes. Claim 1 allows phenyl unsubstituted or substituted with at least one halo group; Claim 6 specifies fluoro as a further narrowing.
-
Does the patent include use as an anticonvulsant for CNS disorders in humans?
Yes. Claims 11-13 cover treating CNS disorders in an animal, with mammal and human limitations and an anticonvulsant effective amount administration requirement.
-
Does the patent cover both the active ingredient and finished products?
Yes. Claim 10 covers a therapeutic composition with a pharmaceutical carrier, and Claims 11-13 cover administration methods.
References
[1] United States Reissue Patent RE38551. Claims as provided in the prompt (Claims 1-13).
